These fast-growing companies have new personnel announcements to share. Photos courtesy

Three Houston startups have new hires they're excited about. From new board members to C-level execs, here's who's moving and shaking in Houston innovation.

Software company hires new product exec

Photo courtesy of Cart.com

Cart.com, an end-to-end e-commerce services provider, announced Michael Svatek as the company's first chief product officer. Formerly, Svatek served as chief product and strategy officer at Bazaarvoice and then co-founded and served as the CEO and head of product at Rivet Works, a cloud software platform.

"Michael's deep expertise across the e-commerce technology value chain coupled with his experience in M&A, strategic alliances, and entrepreneurship are one-of-a-kind in this industry, and a testament to our growth and trajectory at Cart.com," says Omair Tariq, Cart.com co-founder and CEO, in a news release. "We are so pleased to welcome Michael, a proven leader with an innate understanding of the Cart.com mission to unify and streamline the fragmented e-commerce value chain for brands of any size."

Earlier this year, Cart.com raised a $25 million series A funding round and emerged from stealth mode.

Fast-growing e-commerce startup lawyers up

Photo courtesy of GoExpedi

Houston-based GoExpedi, another tech company disrupting e-commerce, once again expanded its executive board, naming Julie Gremillion as general counsel. She has more than 10 years of experience in working with energy companies, and will lead the company's legal strategy, managing compliance and risk throughout the organization, and more.

"We are thrilled to have found Julie, one of the most experienced, savvy and well-rounded legal counsels in the industry," says Tim Neal, GoExpedi CEO, in a news release. "Her legal background in the energy space is beyond reproach. As we enter this next critical phase of growth, Julie's combined commercial and legal expertise will provide us with a platform for long-term and sustainable success."

GoExpedi also recently fundraised a $25 million round last fall.

Recently acquired therapeutics company adds board member

Photo via aiche.org

Clinical-stage biotechnology company, Coya Therapeutics Inc. has appointed Ann Lee., senior vice president of Cell Therapy Development and Operations at Bristol Myers Squibb, to the company's board of directors.

"Dr. Lee is one of the leading cell therapy technical development, supply chain and manufacturing executives in the biopharmaceutical industry," says Howard Berman, Coya CEO, says in a release. "At Coya, we are revolutionizing cell therapy manufacturing and supply chain management via proprietary cryopreservation to overcome prior limitations of Treg cell therapies. Dr. Lee's expertise will be instrumental as we advance in the clinic and build out manufacturing partnerships."

The company, which focuses on creating therapeutics for neurodegenerative and autoimmune diseases, announced earlier this year that it has completed a merger with Nicoya Health Inc. and raised $10 million in its series A.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.